ATE204751T1 - Mittel zur arzneistoffabgabe im colon - Google Patents

Mittel zur arzneistoffabgabe im colon

Info

Publication number
ATE204751T1
ATE204751T1 AT95922632T AT95922632T ATE204751T1 AT E204751 T1 ATE204751 T1 AT E204751T1 AT 95922632 T AT95922632 T AT 95922632T AT 95922632 T AT95922632 T AT 95922632T AT E204751 T1 ATE204751 T1 AT E204751T1
Authority
AT
Austria
Prior art keywords
colon
drug
medicinal
delivery
agents
Prior art date
Application number
AT95922632T
Other languages
English (en)
Inventor
Peter Watts
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Application granted granted Critical
Publication of ATE204751T1 publication Critical patent/ATE204751T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95922632T 1994-06-21 1995-06-21 Mittel zur arzneistoffabgabe im colon ATE204751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412394A GB9412394D0 (en) 1994-06-21 1994-06-21 Colonic drug delivery composition
PCT/GB1995/001458 WO1995035100A1 (en) 1994-06-21 1995-06-21 Colonic drug delivery composition

Publications (1)

Publication Number Publication Date
ATE204751T1 true ATE204751T1 (de) 2001-09-15

Family

ID=10757052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922632T ATE204751T1 (de) 1994-06-21 1995-06-21 Mittel zur arzneistoffabgabe im colon

Country Status (14)

Country Link
US (2) US6228396B1 (de)
EP (1) EP0810857B1 (de)
JP (1) JP2986217B2 (de)
AT (1) ATE204751T1 (de)
AU (1) AU688060B2 (de)
CA (1) CA2193481C (de)
DE (1) DE69522475T2 (de)
DK (1) DK0810857T3 (de)
ES (1) ES2162922T3 (de)
FI (1) FI118626B (de)
GB (1) GB9412394D0 (de)
NO (1) NO315686B1 (de)
PT (1) PT810857E (de)
WO (1) WO1995035100A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
WO1998022095A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB9800912D0 (en) * 1998-01-17 1998-03-11 Danbiosyst Uk New composition
KR20010040646A (ko) * 1998-02-09 2001-05-15 블로닉, 조엘 위장관의 만성 염증성 질환의 치료방법
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
DE19923817A1 (de) * 1999-05-18 2000-11-23 Roland Bodmeier Kapsel mit kontrollierter Wirkstofffreisetzung
WO2000074720A1 (fr) * 1999-06-09 2000-12-14 Mochida Pharmaceutical Co., Ltd. Systeme de liberation dans les voies digestives inferieures
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US6908609B2 (en) 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
ES2376739T3 (es) 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20040253211A1 (en) * 2003-04-30 2004-12-16 Nastech Pharmaceutical Company Inc. Method for diagnosing and treating cancer
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20070078109A1 (en) * 2004-02-13 2007-04-05 David Platt Compositions and methods used to treat acne and candida
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JP5987151B2 (ja) * 2006-09-29 2016-09-07 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 小型閾値センサ
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
EP2061440A2 (de) 2007-04-04 2009-05-27 Sigmoid Pharma Limited Pharmazeutische tacrolimus-zusammensetzung
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090269405A1 (en) * 2008-04-08 2009-10-29 Appian Labs, Llc Enzyme mediated delivery system
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US20120276056A1 (en) * 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
EP2830599B1 (de) * 2012-03-29 2018-08-15 Therabiome, Llc Ortsspezifische gastrointestinale orale impfrezepte zur wirkung am ileum und am blinddarm
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2981289A1 (de) * 2013-04-05 2016-02-10 Polichem SA Verwendung von pidotimod zur behandlung entzündlicher darmerkrankungen
CA2901284A1 (en) 2013-04-05 2014-10-09 Polichem Sa Use of pidotimod to treat irritable bowel syndrome
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3107568B1 (de) * 2014-02-20 2024-03-27 Vaxart, Inc. Formulierungen für kleine intestinale verabreichung
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
KR102678401B1 (ko) 2015-06-12 2024-06-26 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
CN106380636B (zh) * 2016-08-30 2019-05-14 华南理工大学 一种壳聚糖接枝的抗消化淀粉载体材料及其制备方法和应用
CN108201531A (zh) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 高溶解性磺苄西林钠结肠靶向淀粉胶囊及其制备方法
CA3060026A1 (en) 2017-04-18 2018-10-25 Jayant Jagannath Khandare Polymer based formulation for release of drugs and bioactives at specific git sites
JP2021528483A (ja) * 2018-05-03 2021-10-21 エムダブリュ エンキャップ リミテッド 下部胃腸管への医薬の送達のための剤形
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
WO2022222972A1 (zh) 2021-04-20 2022-10-27 江苏恒瑞医药股份有限公司 用于药物特定递送的胶囊及其制备方法
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4738724A (en) * 1983-11-04 1988-04-19 Warner-Lambert Company Method for forming pharmaceutical capsules from starch compositions
US4673438A (en) * 1984-02-13 1987-06-16 Warner-Lambert Company Polymer composition for injection molding
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
DE3869337D1 (de) * 1987-11-20 1992-04-23 Greither Peter Kapsel und verfahren zu ihrer herstellung.
DE8715583U1 (de) * 1987-11-24 1988-01-28 Greither, Peter, Kirchberg Kapsel
DE3812799A1 (de) 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5342624A (en) * 1989-02-16 1994-08-30 British Technology Group Ltd. Dispensing device
WO1990013286A1 (en) 1989-05-11 1990-11-15 Chugai Seiyaku Kabushiki Kaisha Oral preparation which can be released at suitable region in intestine
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
BE1003677A3 (nl) * 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
DE4236025A1 (de) 1992-10-24 1994-04-28 Merck Patent Gmbh Orale Arzneiformen
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
CN1047075C (zh) 1993-02-26 1999-12-08 普罗克特和甘保尔公司 比沙可啶剂型
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
PT621032E (pt) 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
EP0724441A1 (de) 1993-10-19 1996-08-07 The Procter & Gamble Company Natriumpicosulfat enthaltende dosierungsform
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same

Also Published As

Publication number Publication date
WO1995035100A1 (en) 1995-12-28
NO965436L (no) 1996-12-18
PT810857E (pt) 2001-12-28
ES2162922T3 (es) 2002-01-16
JP2986217B2 (ja) 1999-12-06
AU2746095A (en) 1996-01-15
CA2193481A1 (en) 1995-12-28
AU688060B2 (en) 1998-03-05
FI965154A0 (fi) 1996-12-20
JPH09510478A (ja) 1997-10-21
DE69522475T2 (de) 2002-05-08
NO965436D0 (no) 1996-12-18
DE69522475D1 (de) 2001-10-04
US20010026807A1 (en) 2001-10-04
FI965154L (fi) 1997-02-20
NO315686B1 (no) 2003-10-13
CA2193481C (en) 2001-03-20
FI118626B (fi) 2008-01-31
US6228396B1 (en) 2001-05-08
EP0810857B1 (de) 2001-08-29
EP0810857A1 (de) 1997-12-10
DK0810857T3 (da) 2001-10-08
GB9412394D0 (en) 1994-08-10

Similar Documents

Publication Publication Date Title
DE69522475D1 (de) Mittel zur arzneistoffabgabe im colon
YU49354B (sh) Oralne tečne formulacije alendronata
DE59604603D1 (de) Arzneiform zur abgabe von wirkstoffen an wunden
PL357470A1 (en) Pharmaceutical compositions providing enhanced drug concentrations
AU4879396A (en) Use of inorganic aerogels in pharmacy
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
NO20074292L (no) Anvendelse av buprenorfin i polymermatriks og leveringssystemer
CA2141704A1 (fr) Solutions aqueuses concentrees d'argatroban
ATE256460T1 (de) Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler
NO981746D0 (no) Utlevering av biologisk aktive polypeptider
TR199800045T1 (xx) Eczasal bile�imler.
ATE225647T1 (de) Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
AU668767B2 (en) Oral medicament form
UA39884C2 (uk) Таблетка на основі клодронової кислоти, спосіб її одержання та спосіб лікування остеопорозу
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
FR2735132B1 (fr) Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
ATE214263T1 (de) Flüssigkeitsabgabesystem
ES2126265T3 (es) Tableta de accion retardada con un cierto contenido de diclorofenaco de sodio.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE190310T1 (de) Dioxo-thiopyrano-pyridin-carbonsäure-derivate und ihre verwendung als arzneimittel
ATE292954T1 (de) Schutz zur verminderung von zahnbelag
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name